Open access peer-reviewed Edited Volume

Liposomes - Recent Advances, New Perspectives and Applications

Rajeev Tyagi

CSIR - Institute of Microbial Technology, India

A well-known researcher in developing mouse-human chimeras and drug delivery vehicles to study infectious diseases and beyond. Dr. Tyagi obtained his Ph.D. degree at Biomedical Parasitology Unit, Institute Pasteur, Paris, France, and worked at the University of South Florida, Augusta University, and Vanderbilt University Medical Center (VUMC), USA. Currently, he is leading a group at CSIR-Institute of Microbial Technology, India.

Covering

Liposomes Applications Drug Delivery Nanomedicine Cancer Therapy Cancer Nanomedicine Monocytes Ligand Anchoring Lipid Vesicles Transfection Antigen Delivery mRNA Delivery

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

Liposome, a versatile lipid vesicle, is licensed to use for effective delivery of drugs, candidate vaccines, and nucleic acids. Also, drug-loaded ligand anchored liposomes are used to induce selective apoptosis in cells of monocyte and macrophage lineage. Therefore this book aims to cover all spheres of drug and antigen delivery for developing therapeutic interventions and vaccines against infectious diseases and beyond.

This book will shed light on various methods for the preparation and characterization of liposomes and their engineered versions. Technological advancements have enabled us to develop newer methods of formulating liposomes. Over time, liposomes have been modified to a larger extent and engineered to meet our growing needs for sustained and controlled delivery for developing therapeutic interventions vaccines. Further, this book will throw light on the various methods of preparation and characterization of liposomes, and discuss several biochemical and indirect methods to understand the biological and physicochemical mechanisms of action of liposomes that decide their efficiency in vivo.
Despite their limitations such as encapsulation efficiency, liposomes are a well-established choice for a number of unconventional and conventional biological applications. The versatility of these lipid-based vesicles presents the importance of these nanoparticles in the future applications of nanotechnology besides targeted drug delivery. Overall, this book provides the necessary and relevant information about various aspects of liposomes and their use in nanomedicine.
 

Publishing process

Book initiated and editor appointed

Date completed: February 22nd 2022

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline Extended: Open for Submissions

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Approved chapters written in full and submitted

Deadline for full chapters: May 21st 2022

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: August 9th 2022

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: October 8th 2022

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Rajeev Tyagi

CSIR - Institute of Microbial Technology, India

Dr. Rajeev K. Tyagi earned Ph.D. degree at Biomedical Parasitology Unit, Institute Pasteur, Paris, France in June 2011 on a very challenging and interesting topic of malaria immunology/parasitology. He developed a long lasting, stable and straightforward laboratory animal model (humanized mouse model: a versatile mouse model) to study biology and immunology of infectious diseases and beyond. Dr. Tyagi worked as postdoc fellow in the laboratory of Dr. John Adams, University of South Florida, USA and received training to explore the potential of the developed “humanized mouse” to characterize attenuated asexual blood stage falciparum parasite to understand the innate immune response of the attenuated parasite (growth mutant). Also, he developed small laboratory human liver chimeric mice by transplanting the human hepatocytes in transgenic/immunodeficient mice (TK/NOG) at USF to study the least known liver stage infection of P. falciparum. Later on, he discovered novel dendritic like cell population called “pathogen differentiated dendritic cells (PDDCs)” when incubated with P. gingivalis and tracking of monocyte derived dendritic cells (MoDcs) in a reconstituted immunodeficient NOD.PrkdcscidIl2rg-/- (NSG) mice was carried out at Augusta University, USA to understand the host-pathogen interaction. Dr. Tyagi at the Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition Vanderbilt University Medical Centre (VUMC), USA deployed his efforts to understand the role of IL-23R in the modulation of functioning of regulatory T cells and its role in the pathogenesis of colitis in an experimental humanized mouse. Currently, Dr. Tyagi has been leading a group at CSIR-Institute of Microbial Technology, Chandigarh, India and his lab is focused to: 1. Developing human-liver chimeric mice for huHep transplantation to study liver stage infection of P. falciparum and transition to asexual blood stage infection to test antimalarial drugs and vaccine candidates in one host. 2. Study of drug resistance against Plasmodium falciparum 3. Dendritic cells as "therapeutic vaccines" playing a crucial role in translational biomedical research. 4. Formulation and characterization of nanoscale drug carriers to deliver methotrexate (MTX) and aceclofenac to address Rheumatoid Arthritis, cancer and other inflammatory diseases as well as candidate vaccines.

View profile

Book chapters authored 1

Books edited 2

Introducing your Author Service Manager

Ms. Martina Ivancic

As an Author Service Manager, my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question
creativecommons
alpsp
cope
stm
ithenticate
crossref
doi
oaspa

Book will be abstracted and indexed in

googlescholar
worldcat
base
az
openaire